South Korea-based Alteogen has signed an exclusive licensing deal worth up to $365m with a global pharmaceutical company, granting worldwide rights to develop and commercialise a subcutaneous biologic product using its Hybrozyme technology.
The agreement involves access to ALT-B4 (berahyaluronidase alfa), a recombinant human hyaluronidase created with Alteogen’s Hybrozyme platform.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
This technology is intended to convert biologics typically given via intravenous infusion into more convenient subcutaneous formulations.
Under the agreement, Alteogen is set to receive an upfront payment and could earn additional amounts through development, regulatory, and sales milestone payments.
The company will also receive royalties on net sales for any product commercialised using this technology.
Alteogen CEO Tae-Yon Chun said: “We are pleased to enter into this licence agreement with a global leader with a long-standing commitment to advancing innovative therapies for patients with serious unmet medical needs.
“We will continue to accelerate the growth of our platform technology through strategic global partnerships.”
ALT-B4, which is provided to the counterparty under the licence, allows biologics normally given intravenously to be converted into subcutaneous formulations.
The technology achieves this by temporarily breaking down hyaluronan in the extracellular matrix, which facilitates faster and more efficient absorption and dispersion of drugs administered together with ALT-B4.
Alteogen operates in the development and commercialisation of biologics, such as antibody-drug conjugates, biobetters, and biosimilars.
Its pipeline includes clinical-stage long-acting therapeutic proteins and next-generation antibody-drug conjugates that use its proprietary NexP-fusion and NexMab platform technologies.
Developed since Alteogen’s founding in 2008, its Hybrozyme technology enables subcutaneous delivery of medicines that are typically administered intravenously.
In March 2025, AstraZeneca entered an exclusive licence agreement with bio-platform company Alteogen, involving the latter’s hyaluronidase utilising Hybrozyme platform technology, ALT-B4, to develop subcutaneous formulations of several oncology assets.
